The Source Blog
Trends in Price and Quality Transparency
All Payer Claims Databases (APCD)
For more on APCD’s, check out our Legislative Topics: All Payer Claims Databases overview on Medium.
- Key:
- Mandatory, Existing
- Mandatory, Implementing
- Voluntary
- Private
Pharmaceutical Price Transparency Legislation
For more on this legislation, refer to our Issue Brief on The Source Blog and the NASHP Center for Rx Pricing.
- Key:
- Price Transparency Legislation
Recent Action in Price and Quality Transparency
SB 992 (see companion bill HB 1338) – Maryland
Introduced: 2019 Status: Inactive / Dead
Requiring the Prescription Drug Monitoring Program to disclose prescription monitoring data, in accordance with certain regulations, to the medical director or authorized administrator of certain health care facilities, or the medical director’s or authorized administrator’s …
SB 819 (see companion bill HB 920) – Maryland
Introduced: 2019 Status: Inactive / Dead
Requiring the Secretary of Health, by a certain date each year, to identify a certain number of certain prescription drugs on which the State spends a certain amount of money; requiring the Secretary to require …
SB 803 – Maryland
Introduced: 2019 Status: Inactive / Dead
Requiring certain hospitals to provide each patient with written notice that includes certain information related to outpatient facility fees that are charged for services provided at the hospital; requiring the Health Education and Advocacy Unit …
SB 759 (see companion bill HB 768) – Maryland
Introduced: 2019 Status: Inactive / Dead
Establishing the Prescription Drug Affordability Board; providing for the purpose of the Board; providing for the membership of the Board; requiring certain conflicts of interest to be disclosed and considered when appointing members to the …
HB 989 – Maryland
Introduced: 2019 Status: Inactive / Dead
Altering the circumstances under which the Maryland Insurance Commissioner is authorized to designate a system as the multi-carrier common online provider directory information system; and altering the manner in which and circumstances under which a …
HB 849 – Maryland
Introduced: 2019 Status: Inactive / Dead
Requiring certain hospitals to provide each patient with written notice that includes certain information related to outpatient facility fees that are charged for services provided at the hospital; requiring the Health Education and Advocacy Unit …
HB 768 (see companion bill SB 759) – Maryland
Introduced: 2019 Status: Enacted
Establishing the Prescription Drug Affordability Board as an instrumentality of the State the purpose of which is to protect State residents and certain stakeholders within the health care system from the high costs of prescription …
Next | See all Legislation Records
Introduced: 2019 Status: Inactive / Dead
Requiring the Prescription Drug Monitoring Program to disclose prescription monitoring data, in accordance with certain regulations, to the medical director or authorized administrator of certain health care facilities, or the medical director’s or authorized administrator’s …
SB 819 (see companion bill HB 920) – Maryland
Introduced: 2019 Status: Inactive / Dead
Requiring the Secretary of Health, by a certain date each year, to identify a certain number of certain prescription drugs on which the State spends a certain amount of money; requiring the Secretary to require …
SB 803 – Maryland
Introduced: 2019 Status: Inactive / Dead
Requiring certain hospitals to provide each patient with written notice that includes certain information related to outpatient facility fees that are charged for services provided at the hospital; requiring the Health Education and Advocacy Unit …
SB 759 (see companion bill HB 768) – Maryland
Introduced: 2019 Status: Inactive / Dead
Establishing the Prescription Drug Affordability Board; providing for the purpose of the Board; providing for the membership of the Board; requiring certain conflicts of interest to be disclosed and considered when appointing members to the …
HB 989 – Maryland
Introduced: 2019 Status: Inactive / Dead
Altering the circumstances under which the Maryland Insurance Commissioner is authorized to designate a system as the multi-carrier common online provider directory information system; and altering the manner in which and circumstances under which a …
HB 849 – Maryland
Introduced: 2019 Status: Inactive / Dead
Requiring certain hospitals to provide each patient with written notice that includes certain information related to outpatient facility fees that are charged for services provided at the hospital; requiring the Health Education and Advocacy Unit …
HB 768 (see companion bill SB 759) – Maryland
Introduced: 2019 Status: Enacted
Establishing the Prescription Drug Affordability Board as an instrumentality of the State the purpose of which is to protect State residents and certain stakeholders within the health care system from the high costs of prescription …
Next | See all Legislation Records
Pharmaceutical Care Management v. Rutledge – Arkansas
District Court: Eastern District of Arkansas Status: Decided
The 8th Circuit held that both ERISA and Medicare Part D preempted Arkansas’ drug pricing law Act 900 (SB 688). Act 900 requires disclosure of …
PhRMA v. David – California
District Court: Eastern District of California Status: Pending
PhRMA is challenging California’s drug price transparency law SB 17 alleging that the law is unconstitutional because it violates the Commerce Clause, the First Amendment, …
Association for Accessible Medicines v. Frosh – Maryland
District Court: District of Maryland Status: Decided
In a significant victory for the pharmaceutical industry, the 4th U.S. Circuit Court of Appeals found Maryland’s landmark 2017 law (HB 631), which punishes generic …
PhRMA and BIO v. Sandoval – Nevada
District Court: District of Nevada Status: Decided
In September 2017, just three months after Nevada passed its insulin transparency law (SB 539) in June 2017 to increase transparency over the price of …
See all Litigation Records
District Court: Eastern District of Arkansas Status: Decided
The 8th Circuit held that both ERISA and Medicare Part D preempted Arkansas’ drug pricing law Act 900 (SB 688). Act 900 requires disclosure of …
PhRMA v. David – California
District Court: Eastern District of California Status: Pending
PhRMA is challenging California’s drug price transparency law SB 17 alleging that the law is unconstitutional because it violates the Commerce Clause, the First Amendment, …
Association for Accessible Medicines v. Frosh – Maryland
District Court: District of Maryland Status: Decided
In a significant victory for the pharmaceutical industry, the 4th U.S. Circuit Court of Appeals found Maryland’s landmark 2017 law (HB 631), which punishes generic …
PhRMA and BIO v. Sandoval – Nevada
District Court: District of Nevada Status: Decided
In September 2017, just three months after Nevada passed its insulin transparency law (SB 539) in June 2017 to increase transparency over the price of …
See all Litigation Records
News & Opinions
Articles & Reports
The Commonwealth Fund November 11, 2019
The Commonwealth Fund October 30, 2019
USC-Brookings Schaeffer Initiative for Health Policy October 24, 2019
Health Affairs Blog October 17, 2019
The Commonwealth Fund October 30, 2019
USC-Brookings Schaeffer Initiative for Health Policy October 24, 2019
Health Affairs Blog October 17, 2019